Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients

被引:5
作者
Tajuelo, Ana [1 ]
Carretero, Octavio [2 ]
Garcia-Rios, Estefani [3 ,4 ]
Lopez-Siles, Mireia [1 ]
Cano, Olga [5 ]
Vazquez, Monica [5 ]
Mas, Vicente [5 ]
Rodriguez-Goncer, Isabel [2 ]
Lalueza, Antonio [6 ,7 ]
Lopez-Medrano, Francisco [2 ,7 ,8 ]
Juan, Rafael San [2 ,7 ,8 ]
Fernandez-Ruiz, Mario [2 ,7 ,8 ]
Aguado, Jose Ma [2 ,7 ,8 ]
McConnell, Michael J. [1 ]
Perez-Romero, Pilar [3 ]
机构
[1] Inst Salud Carlos III ISCIII, Intrahosp Infect Lab, Natl Ctr Microbiol, Madrid, Spain
[2] Hosp Universitario12 Octubre, Inst Invest Sanitaria Hosp Octubre 12 imas 12, Unit Infect Dis, Madrid, Spain
[3] Inst Salud Carlos III ISCIII, Natl Ctr Microbiol, Infecc Vir & Inmun Enfermos Inmunodeprimidos, Madrid, Spain
[4] Univ Int Valencia, VIU, Valencia, Spain
[5] Inst Salud Carlos III ISCIII, Natl Ctr Microbiol, Biol Viral, Madrid, Spain
[6] Hosp Universitario12 Octubre, Inst Invest Sanitaria Hosp Octubre 12 imas12, Dept Internal Med, Madrid, Spain
[7] Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
[8] Univ Complutense, Dept Med, Madrid, Spain
关键词
SARS-CoV-2; COVID disease severity; humoral response; IgG; IgM; 2; NEUTRALIZING ANTIBODIES; HOSPITALIZED-PATIENTS; COVID-19; KINETICS; MORTALITY; RESPONSES; REVEAL;
D O I
10.3389/fimmu.2022.878812
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionThere is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients. MethodsA prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed. ResultsPatients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors (p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (p< 0.001), and than patients who required oxygen therapy (p< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (p< 0.001) and those who needed oxygen therapy (p< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (p< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived (p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p <= 0.0036). ConclusionsWe demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection.
引用
收藏
页数:10
相关论文
共 48 条
[1]   SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Coyle, Peter ;
Malek, Joel A. ;
Ahmed, Ayeda A. ;
Mohamoud, Yasmin A. ;
Younuskunju, Shameem ;
Ayoub, Houssein H. ;
Al Kanaani, Zaina ;
Al Kuwari, Einas ;
Butt, Adeel A. ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar Hassan ;
Latif, Ali Nizar ;
Shaik, Riyazuddin Mohammad ;
Rahim, Hanan F. Abdul ;
Nasrallah, Gheyath K. ;
Yassine, Hadi M. ;
Al Kuwari, Mohamed Ghaith ;
Al Romaihi, Hamad Eid ;
Al-Thani, Mohamed H. ;
Al Khal, Abdullatif ;
Bertollini, Roberto .
ECLINICALMEDICINE, 2021, 35
[2]   Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate [J].
Addetia, Amin ;
Crawford, Katharine H. D. ;
Dingens, Adam ;
Zhu, Haiying ;
Roychoudhury, Pavitra ;
Huang, Meei-Li ;
Jerome, Keith R. ;
Bloom, Jesse D. ;
Greninger, Alexander L. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (11)
[3]  
Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]
[4]   Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency [J].
Arroyo-Sanchez, Daniel ;
Cabrera-Marante, Oscar ;
Laguna-Goya, Rocio ;
Almendro-Vazquez, Patricia ;
Carretero, Octavio ;
Javier Gil-Etayo, Francisco ;
Suarez-Fernandez, Patricia ;
Perez-Romero, Pilar ;
Rodriguez de Frias, Edgard ;
Serrano, Antonio ;
Allende, Luis M. ;
Pleguezuelo, Daniel ;
Paz-Artal, Estela .
JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (02) :240-252
[5]   Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein [J].
Battles, Michael B. ;
Mas, Vicente ;
Olmedillas, Eduardo ;
Cano, Olga ;
Vazquez, Monica ;
Rodriguez, Laura ;
Melero, Jose A. ;
McLellan, Jason S. .
NATURE COMMUNICATIONS, 2017, 8
[6]   Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 [J].
Chen, Xiangyu ;
Pan, Zhiwei ;
Yue, Shuai ;
Yu, Fei ;
Zhang, Junsong ;
Yang, Yang ;
Li, Ren ;
Liu, Bingfeng ;
Yang, Xiaofan ;
Gao, Leiqiong ;
Li, Zhirong ;
Lin, Yao ;
Huang, Qizhao ;
Xu, Lifan ;
Tang, Jianfang ;
Hu, Li ;
Zhao, Jing ;
Liu, Pinghuang ;
Zhang, Guozhong ;
Chen, Yaokai ;
Deng, Kai ;
Ye, Lilin .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
[7]   Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients [J].
Dessie, Zelalem G. ;
Zewotir, Temesgen .
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[8]   Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival [J].
Dispinseri, Stefania ;
Secchi, Massimiliano ;
Pirillo, Maria Franca ;
Tolazzi, Monica ;
Borghi, Martina ;
Brigatti, Cristina ;
De Angelis, Maria Laura ;
Baratella, Marco ;
Bazzigaluppi, Elena ;
Venturi, Giulietta ;
Sironi, Francesca ;
Canitano, Andrea ;
Marzinotto, Ilaria ;
Tresoldi, Cristina ;
Ciceri, Fabio ;
Piemonti, Lorenzo ;
Negri, Donatella ;
Cara, Andrea ;
Lampasona, Vito ;
Scarlatti, Gabriella .
NATURE COMMUNICATIONS, 2021, 12 (01)
[9]   SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus [J].
Dogan, Mikail ;
Kozhaya, Lina ;
Placek, Lindsey ;
Gunter, Courtney ;
Yigit, Mesut ;
Hardy, Rachel ;
Plassmeyer, Matthew ;
Coatney, Paige ;
Lillard, Kimberleigh ;
Bukhari, Zaheer ;
Kleinberg, Michael ;
Hayes, Chelsea ;
Arditi, Moshe ;
Klapper, Ellen ;
Merin, Noah ;
Liang, Bruce Tsan-Tang ;
Gupta, Raavi ;
Alpan, Oral ;
Unutmaz, Derya .
COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[10]  
Feng S., 2021, NAT MED, V27, P2032, DOI [DOI 10.1038/s41591-021-01540-1, 10.1038/s41591-021-01540-1, 10.1101/2021.06.21.21258528]